Erbe introduces FiAPC® plus: Advancing control in flexible argon plasma coagulation
Erbe Elektromedizin GmbH presents its latest innovation in electrosurgery: the FiAPC® plus probes. They are designed for use in gastrointestinal and pulmonary endoscopy. Building upon decades of experience with argon plasma coagulation (APC), FiAPC® plus probes introduce advancements aimed at enhancing control, workflow efficiency, and procedural reliability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714417615/en/
Various versions of the FiAPC® plus probes with axial, lateral and circumferential openings available.
Designed to put control in the physician’s hands
With the FiAPC® plus probes, Erbe seeks to give physicians greater control over every aspect of the APC application: from energy delivery and beam formation to tip positioning and suction. "Precision in APC begins with control. And that’s exactly what FiAPC® plus is built to provide," Mariuccia Zambelli, Vice President Global Marketing, stated.
The new probes feature a thermally insulated tip, developed to minimize heat generation at the distal end of the instrument. This reduces tissue sticking and allows for a homogenous and consistent plasma beam, even in complex anatomies.
Versatility for GI and pulmonary applications
The FiAPC® plus probes are available in various versions with axial, lateral and circumferential openings for the plasma beam, offering physicians options that align with a wide range of clinical applications. The probes are compatible with Erbe’s full range of renowned APC modes - preciseAPC®, pulsedAPC® (slow and fast), and forcedAPC® - which can be selected to choose the right tissue effect for the corresponding tissue characteristics.
The FiAPC® plus probes unfold their full potential in combination with the APC 3 and the new VIO® 3n Fire electrosurgical generator, specifically dedicated to APC applications. The platform's architecture ensures seamless integration, fast recognition, and preconfigured APC mode settings tailored to the FiAPC® plus probe, resulting in enhanced workflow efficiency, precision, and user confidence.
Reliable performance in thermosensitive areas across specialties
While the FiAPC® plus probes are designed for a broad range of APC indications, their value becomes especially clear in procedures involving thermosensitive areas, whether in the gastrointestinal tract or the bronchial system. In areas such as the cecum, right colon, or narrow airways, where precision and limited thermal spread are essential, FiAPC® plus offers reliability and control through stable plasma ignition, reduced tissue sticking, and optimized energy delivery at the probe tip.
To support GI endoscopists and pulmonologists in applying APC, Erbe complements the launch of FiAPC® plus with a comprehensive offering of clinical education and training. This includes hands-on courses, structured learning modules, and on-site support through the Erbe Team: helping physicians navigate their APC journey from first use to expert application.
FiAPC® plus probes are now available in CE and CE-related markets. Additional markets will follow soon. With this latest development, Erbe reaffirms its commitment to pushing the boundaries of APC technology through user-centered innovation and clinical partnership.
To get into control visit the FiAPC plus website now.
[https://en.erbe-med.com/en-en/highlights/fiapc/]
About Erbe Elektromedizin
Erbe Elektromedizin develops, manufactures, and distributes surgical instruments and devices worldwide, while providing services for professional use of these products in a diverse range of medical disciplines. Surgeons, OR teams and patients around the world rely on Erbe medical technology. The surgical instruments and devices find use in almost all specialist areas. They are based on electrosurgery combined with other Erbe technologies. Hybrid solutions enable us to provide new, innovative applications in medicine.
Fields of activity
- Imaging
- Endoscopy
- Electrosurgery
- Plasma surgery
- Thermofusion
- Hydrosurgery
- Cryo technology
An international network
- 20 international sales and service units
- 5 production sites
- Erbe is active in 110 international markets.
The Erbe workforce
- 2,100 employees worldwide
- Some 1,100 of them in Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20250714417615/en/
Contacts
Erbe Elektromedizin GmbH
Waldhoernlestrasse 17
72072 Tuebingen
erbe-med.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fen.erbe-med.co
m%2Fen-en%2Fhighlights%2Ffiapc%2F%3Fmtm_campaign%3DFiAPC%2520Plus%26mtm_source%3
DPR&esheet=54289214&newsitemid=20250714417615&lan=en-US&anchor=erbe-med.com&inde
x=3&md5=3252ee35fdab68ddca72c5b4f6160fbc
info@erbe-med.com
Contacts
David Malecki
Phone +49 7071 755-316
david.malecki@erbe-med.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Align Partners Sends Second Public Shareholder Letter to Coway, Urging Announcement of Revised Value-up Plan by January 30, 202615.12.2025 15:54:00 CET | Press Release
Align Partners Capital Management Inc. (“Align Partners”), a shareholder of Coway Co., Ltd. (“Coway”) since 2023 holding more than 4% of the Company’s outstanding shares through funds it manages or advises, announced that it has sent a second public shareholder letter to Coway’s Board of Directors. The letter calls for measures to address the company’s chronic undervaluation and enhance shareholder value. Align Partners has requested that Coway announce a revised corporate Value-up Plan reflecting these proposals by January 30, 2026. In the letter, Align Partners assessed Coway’s February 2025 plan as insufficient to address Coway’s persistent undervaluation and urged the Board to incorporate seven measures: (1) clear mid-to-long-term valuation and ROE targets with execution plans; (2) clarified and strengthened target capital structure policy; (3) updated shareholder return policy reflecting both the target capital structure policy and new dividend income tax separation regime; (4) en
Marathon Asset Management Provides Junior Capital Financing to EXALTA Group15.12.2025 15:00:00 CET | Press Release
Marathon Asset Management (“Marathon”), a leading global credit manager with more than $24 billion of assets under management, is pleased to announce the closing of a junior capital financing to EXALTA Group (“EXALTA” or the “Company”), a portfolio company of Montagu. Marathon led the financing that supported the formation of EXALTA through the strategic merger of three Montagu-owned companies including Intech, Resolve Surgical Technologies, and Tyber Medical. The transaction marks one of many successful transactions for Marathon’s European Credit business in the healthcare sector, where the firm has a knowledge-based advantage with a dedicated Healthcare Finance business and specialized medical advisory board providing sector insight to middle market companies. EXALTA is a global leader in orthopaedic contract design and manufacturing for spine, trauma, extremities, sports medicine and enabling technology providing comprehensive solutions to OEMs within the medical technology industry
Aurobay Technologies Expands Digital Transformation Partnership With HCLTech to Boost Manufacturing Excellence and Innovation15.12.2025 14:29:00 CET | Press Release
HCLTech, a leading global technology company, and Aurobay Technologies, a division of Horse Powertrain and a global leader in hybrid and low-emission powertrain solutions, have expanded their digital transformation partnership to support Aurobay’s global growth strategy. The expanded partnership establishes HCLTech as Aurobay Technologies’ trusted partner for managing and optimizing SAP, Siemens Teamcenter PLM software and integration services in Sweden and China. This will unlock cost efficiency, operational resilience and digital innovation across Aurobay’s manufacturing and engineering functions by leveraging HCLTech’s flagship service transformation platform, AI Force. The engagement spans core business functions including SAP operations, engineering systems, integration services and mainframe environments, reinforcing Aurobay’s focus on scale, efficiency and seamless operations across global locations. “Horse Powertrain’s division Aurobay Technologies’ digital transformation conti
Applications Now Open for the 5th Cycle of the Mohammed bin Rashid Al Maktoum Global Water Award15.12.2025 14:28:00 CET | Press Release
HE Saeed Mohammed Al Tayer, Chairman of the Board of Trustees of the UAE Water Aid Foundation (Suqia UAE), announced the opening of applications for the 5th cycle of the Mohammed bin Rashid Al Maktoum Global Water Award, offering USD 1 million in prizes. The award seeks to inspire innovative, clean energy–powered solutions for water production, distribution, storage, desalination and purification, supporting global sustainability efforts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215897854/en/ HE Saeed Mohammed Al Tayer, Chairman of the Board of Trustees of the UAE Water Aid Foundation (Suqia UAE) - (Photo: AETOSWire) “Since its establishment, Suqia UAE, launched by His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, has provided clean water to nearly 15 million people in 37 countries worldwide through sustainable development and humanitarian projects.
Novotech Issues White Paper to Help Sponsors Strengthen Early-Phase Oncology Strategy and Execution15.12.2025 14:05:00 CET | Press Release
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, Early-Phase Oncology – Clinical Research Landscape and CRO Enablers (2025), offering in-depth analysis of the key drivers shaping early-phase oncology development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215843975/en/ With approximately 60% of oncology agents progressing from Phase I to Phase II, but only 3–6% reaching regulatory approval, the paper outlines the factors influencing early-stage success, including trial design, patient selection, and regional development pathways. The paper highlights Australia’s continued position as a global first-in-human (FIH) and early-phase research hub. Its ethics-led review frameworks, which can support trial initiation within roughly 4–8 weeks, combined with established FIH centers, oncology networks, and cost efficiencies, position Au
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom